

DAFTAR PUSTAKA

- Alvarez, G., Chrusch, C., Hulme, T., & Posadas-Calleja, J. G. (2019). Renal replacement therapy: a practical update. *Canadian Journal of Anesthesia*, 66(5), 593–604. <https://doi.org/10.1007/s12630-019-01306-x>
- Ankawi, G., Fan, W., Pomarè Montin, D., Lorenzin, A., Neri, M., Caprara, C., De Cal, M., & Ronco, C. (2019). A New Series of Sorbent Devices for Multiple Clinical Purposes: Current Evidence and Future Directions. *Blood Purification*, 47(1–3), 94–100. <https://doi.org/10.1159/000493523>
- Ankawi, G., Neri, M., Zhang, J., Breglia, A., Ricci, Z., & Ronco, C. (2018). Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. *Critical Care*, 22(1), 1–16. <https://doi.org/10.1186/s13054-018-2181-z>
- Argyropoulos, C. P., Chen, S. S., Ng, Y. H., Roumelioti, M. E., Shaffi, K., Singh, P. P., & Tzamaloukas, A. H. (2017). Rediscovering Beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. *Frontiers in Medicine*, 4(JUN). <https://doi.org/10.3389/fmed.2017.00073>
- Bansal, N., Artinian, N. T., Bakris, G., Chang, T., Cohen, J., Flythe, J., Lea, J., Vongpatanasin, W., & Chertow, G. M. (2023). Hypertension in Patients Treated with In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement from the American Heart Association. *Hypertension*, 80(6), E112–E122. <https://doi.org/10.1161/HYP.0000000000000230>
- Beck, W., Techert, F., Lebsanft, H., Haug, U., Deppisch, R., Ledebro, I., & Wizemann, V. (2013). Treatment frequency and efficiency in hemodiafiltration. *Blood Purification*, 35(1–3), 224–229. <https://doi.org/10.1159/000348444>
- Bello, A. K., Okpechi, I. G., Osman, M. A., Cho, Y., Htay, H., Jha, V., Wainstein, M., & Johnson, D. W. (2022). Epidemiology of haemodialysis outcomes. *Nature Reviews Nephrology*, 18(6), 378–395. <https://doi.org/10.1038/s41581-022-00542-7>
- Chen, S. J., Jiang, G. R., Shan, J. P., Lu, W., Huang, H. D., Ji, G., Wu, P., Wu, G. F., Wang, W., Zhu, C., & Bian, F. (2011). Combination of maintenance hemodialysis with hemoperfusion: A safe and effective model of artificial kidney. *International Journal of Artificial Organs*, 34(4), 339–347. <https://doi.org/10.5301/IJAO.2011.7748>
- Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic Kidney Disease Diagnosis and Management: A Review. *JAMA - Journal of the American Medical Association*, 322(13), 1294–1304. <https://doi.org/10.1001/jama.2019.14745>
- Cheung, A. K., Rocco, M. V., Yan, G., Leypoldt, J. K., Levin, N. W., Greene, T., Agodoa, L., Bailey, J., Beck, G. J., Clark, W., Levey, A. S., Ornt, D. B., Schulman, G., Schwab, S., Teehan, B., & Eknoyan, G. (2006). Serum β -2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. *Journal of the American Society of Nephrology*, 17(2), 546–555. <https://doi.org/10.1681/ASN.2005020132>

- Ciceri, P., & Cozzolino, M. (2021). Expanded haemodialysis as a current strategy to remove uremic toxins. *Toxins*, *13*(6), 1–14. <https://doi.org/10.3390/toxins13060380>
- Clark, W. R., Dehghani, N. L., Narsimhan, V., & Ronco, C. (2019). Uremic Toxins and their Relation to Dialysis Efficacy. *Blood Purification*, *48*(4), 299–314. <https://doi.org/10.1159/000502331>
- Cozzolino, M., Mangano, M., Stucchi, A., Ciceri, P., Conte, F., & Galassi, A. (2018). Cardiovascular disease in dialysis patients. *Nephrology Dialysis Transplantation*, *33*, iii28–iii34. <https://doi.org/10.1093/ndt/gfy174>
- Eknoyan, G., Beck, G. J., Cheung, A. K., Daugirdas, J. T., Greene, T., Kusek, J. W., Allon, M., Bailey, J., Delmez, J. A., Depner, T. A., Dwyer, J. T., Levey, A. S., Levin, N. W., Milford, E., Ornt, D. B., Rocco, M. V, Schulman, G., Schwab, S. J., Teehan, B. P., & Toto, R. (2002). Effect of dialysis dose and membrane flux in maintenance hemodialysis. *The New England Journal of Medicine*, *347*(25), 2010–2019. <https://doi.org/10.1056/NEJMoa021583>
- Elshahat, S., Cockwell, P., Maxwell, A. P., Griffin, M., O'Brien, T., & O'Neill, C. (2020). The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. *PLoS ONE*, *15*(3), 1–19. <https://doi.org/10.1371/journal.pone.0230512>
- Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C. W., Brown, J. C., Friedman, J., He, J., Heuton, K. R., Holmberg, M., Patel, D. J., Reidy, P., Carter, A., Cercy, K., ... Murray, C. J. L. (2018). Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *The Lancet*, *392*(10159), 2052–2090. [https://doi.org/10.1016/S0140-6736\(18\)31694-5](https://doi.org/10.1016/S0140-6736(18)31694-5)
- Fujii, H., Goto, S., & Fukagawa, M. (2018). Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction. *Toxins*, *10*(5). <https://doi.org/10.3390/toxins10050202>
- Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013). Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet (London, England)*, *382*(9889), 339–352. [https://doi.org/10.1016/S0140-6736\(13\)60595-4](https://doi.org/10.1016/S0140-6736(13)60595-4)
- Gao, X. F., Li, J. D., Guo, L., Guo, S. S., Zhang, R., Gou, Y. L., & Chen, H. (2018). Effect of Hybrid Blood Purification Treatment on Secondary Hyperparathyroidism for Maintenance Hemodialysis Patients. *Blood Purification*, *46*(1), 19–26. <https://doi.org/10.1159/000486844>
- Genovesi, S., Boriani, G., Covic, A., Vernooij, R. W. M., Combe, C., Burlacu, A., Davenport, A., Kanbay, M., Kirmizis, D., Schneditz, D., van der Sande, F., & Basile, C. (2021). Sudden cardiac death in dialysis patients: different causes and management strategies. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, *36*(3), 396–405. <https://doi.org/10.1093/ndt/gfz182>
- Ghannoum, M., Bouchard, J., Nolin, T. D., Ouellet, G., & Roberts, D. M. (2014). Hemoperfusion for the treatment of poisoning: Technology, determinants of poison clearance, and application in clinical practice. *Seminars in Dialysis*,

- 27(4), 350–361. <https://doi.org/10.1111/sdi.12246>
- Goodkin, D. A., Bieber, B., Jadoul, M., Martin, P., Kanda, E., & Pisoni, R. L. (2017). Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. *Clinical Journal of the American Society of Nephrology: CJASN*, 12(2), 287–297. <https://doi.org/10.2215/CJN.07940716>
- Group, K. D. I. G. O. (KDIGO) C. W. (2013). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*, 3, 1–150.
- Gupta, R., Woo, K., & Yi, J. A. (2021). Epidemiology of end-stage kidney disease. *Seminars in Vascular Surgery*, 34(1), 71–78. <https://doi.org/10.1053/j.semvascsurg.2021.02.010>
- Hamza, E., Metzinger, L., & Metzinger-Le Meuth, V. (2020). Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review. *Cells*, 9(9). <https://doi.org/10.3390/cells9092039>
- Huu, D. N., Quy, Q. D. B., Thu, H. N. T., The, C. P., Hong, Q. N. T., Duc, L. N., Do, Q., & Le Viet, T. (2021). A Combination of Hemodialysis with Hemoperfusion Helped to Reduce the Cardiovascular-Related Mortality Rate after a 3-Year Follow-Up: A Pilot Study in Vietnam. *Blood Purification*, 50(1), 65–72. <https://doi.org/10.1159/000507912>
- Jager, K. J., Kovesdy, C., Langham, R., Rosenberg, M., Jha, V., & Zoccali, C. (2019). A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. *Nephrology Dialysis Transplantation*, 34(11), 1803–1805. <https://doi.org/10.1093/ndt/gfz174>
- Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021). Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options. *Circulation*, 143(11), 1157–1172. <https://doi.org/10.1161/CIRCULATIONAHA.120.050686>
- Jin, Y., Zhang, S., Xiao, J., Wang, Z., Dong, C., You, L., & Kuai, T. (2023). Association between serum $\beta 2$ -microglobulin levels and the risk of all-cause and cardiovascular disease mortality in chinese patients undergoing maintenance hemodialysis. 1–9.
- Jones, S. M., Ravani, P., Hemmelgarn, B. R., Muruve, D., & Macrae, J. M. (2011). Morphometric and biological characterization of biofilm in tunneled hemodialysis catheters. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 57(3), 449–455. <https://doi.org/10.1053/j.ajkd.2010.10.053>
- Juraschek, S. P., Coresh, J., Inker, L. A., Levey, A. S., Köttgen, A., Foster, M. C., Astor, B. C., Eckfeldt, J. H., & Selvin, E. (2013). Comparison of serum concentrations of β -trace protein, $\beta 2$ -microglobulin, cystatin C, and creatinine in the US population. *Clinical Journal of the American Society of Nephrology: CJASN*, 8(4), 584–592. <https://doi.org/10.2215/CJN.08700812>
- Kanda, E., Muenz, D., Bieber, B., Cases, A., Locatelli, F., Port, F. K., Pecoits-Filho, R., Robinson, B. M., & Perl, J. (2021). Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study. *Clinical Kidney Journal*, 14(5), 1436–1442. <https://doi.org/10.1093/ckj/sfaa155>
- Keefe, J. A., Hwang, S.-J., Huan, T., Mendelson, M., Yao, C., Courchesne, P.,

- Saleh, M. A., Madhur, M. S., & Levy, D. (2019). Evidence for a Causal Role of the SH2B3- β (2)M Axis in Blood Pressure Regulation. *Hypertension (Dallas, Tex. : 1979)*, 73(2), 497–503. <https://doi.org/10.1161/HYPERTENSIONAHA.118.12094>
- Kemenkes RI. (2015). Pedoman Umum Pengendalian Obesitas. In *Gastronomia ecuatoriana y turismo local*. (Vol. 1, Nomor 69).
- Kittanamongkolchai, W., El-Zoghby, Z. M., Eileen Hay, J., Wiesner, R. H., Kamath, P. S., LaRusso, N. F., Watt, K. D., Cramer, C. H., & Leung, N. (2017). Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. *Hepatology International*, 11(4), 384–389. <https://doi.org/10.1007/s12072-016-9775-9>
- Klarenbach, S. W., Tonelli, M., Chui, B., & Manns, B. J. (2014). Economic evaluation of dialysis therapies. *Nature Reviews. Nephrology*, 10(11), 644–652. <https://doi.org/10.1038/nrneph.2014.145>
- Leyboldt, J. K., Cheung, A. K., Deeter, R. B., Goldfarb-Rumyantzev, A., Greene, T., Depner, T. A., & Kusek, J. (2004). Kinetics of urea and β 2-microglobulin during and after short hemodialysis treatments. *Kidney International*, 66(4), 1669–1676. <https://doi.org/10.1111/j.1523-1755.2004.00934.x>
- Li, L., Dong, M., & Wang, X. G. (2016). The implication and significance of beta 2 microglobulin: A conservative multifunctional regulator. *Chinese Medical Journal*, 129(4), 448–455. <https://doi.org/10.4103/0366-6999.176084>
- Li, W.-H., Yin, Y.-M., Chen, H., Wang, X.-D., Yun, H., Li, H., Luo, J., & Wang, J.-W. (2017). Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus. *Medicine*, 96(12), e6160. <https://doi.org/10.1097/MD.0000000000006160>
- Liabeuf, S., Lenglet, A., Desjardins, L., Neiryneck, N., Glorieux, G., Lemke, H.-D., Vanholder, R., Diouf, M., Choukroun, G., & Massy, Z. A. (2012). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. *Kidney International*, 82(12), 1297–1303. <https://doi.org/10.1038/ki.2012.301>
- Liu, F. X., Rutherford, P., Smoyer-Tomic, K., Prichard, S., & Laplante, S. (2015). A global overview of renal registries: a systematic review. *BMC Nephrology*, 16, 31. <https://doi.org/10.1186/s12882-015-0028-2>
- Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M. H., Lv, J., Garg, A. X., Knight, J., Rodgers, A., Gallagher, M., Kotwal, S., Cass, A., & Perkovic, V. (2015). Worldwide access to treatment for end-stage kidney disease: A systematic review. *The Lancet*, 385(9981), 1975–1982. [https://doi.org/10.1016/S0140-6736\(14\)61601-9](https://doi.org/10.1016/S0140-6736(14)61601-9)
- Lowenstein, J., & Grantham, J. J. (2017). Residual renal function: a paradigm shift. *Kidney International*, 91(3), 561–565. <https://doi.org/10.1016/j.kint.2016.09.052>
- Lu, W., & Jiang, G. (2022). Hemoperfusion in Maintenance Hemodialysis Patients. *Blood Purification*, 51(10), 803–811. <https://doi.org/10.1159/000525952>
- Ma, Y., Li, S., Tonelli, M., & Unsworth, L. D. (2021). Adsorption-based strategies for removing uremic toxins from blood. *Microporous and Mesoporous Materials*, 319(February), 111035. <https://doi.org/10.1016/j.micromeso.2021.111035>
- Magnani, S., & Atti, M. (2021). Uremic Toxins and Blood Purification: A Review

- of Current Evidence and Future Perspectives. *Toxins*, 13(4).
<https://doi.org/10.3390/toxins13040246>
- Mann, H., Al-Bashir, A., Melzer, H., & Stiller, S. (2003). Diacap® α -polysulfone HI PS: A new dialysis membrane with optimum β 2-microglobulin elimination. *International Journal of Artificial Organs*, 26(6), 461–466.
<https://doi.org/10.1177/039139880302600603>
- Maruyama, Y., Nakayama, M., Abe, M., Yokoo, T., Minakuchi, J., & Nitta, K. (2022). Association between serum β 2-microglobulin and mortality in Japanese peritoneal dialysis patients: A cohort study. *PLoS ONE*, 17(4 April), 1–15. <https://doi.org/10.1371/journal.pone.0266882>
- Morton, R. L., Snelling, P., Webster, A. C., Rose, J., Masterson, R., Johnson, D. W., & Howard, K. (2012). Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease. *CMAJ: Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne*, 184(5), E277-83. <https://doi.org/10.1503/cmaj.111355>
- Mumtaz, A., Anees, M., Bilal, M., & Ibrahim, M. (2010). Beta-2 microglobulin levels in hemodialysis patients. *Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia*, 21(4), 701–706.
- Nguyen, D. B., Shugart, A., Lines, C., Shah, A. B., Edwards, J., Pollock, D., Sievert, D., & Patel, P. R. (2017). National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014. *Clinical Journal of the American Society of Nephrology: CJASN*, 12(7), 1139–1146.
<https://doi.org/10.2215/CJN.11411116>
- Nomura, T., Huang, W.-C., Zhau, H. E., Josson, S., Mimata, H., & Chung, L. W. K. (2014). β 2-Microglobulin-mediated signaling as a target for cancer therapy. *Anti-Cancer Agents in Medicinal Chemistry*, 14(3), 343–352.
<https://doi.org/10.2174/18715206113139990092>
- Nordio, M., Limido, A., Maggiore, U., Nichelatti, M., Postorino, M., & Quintaliani, G. (2012). Survival in patients treated by long-term dialysis compared with the general population. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 59(6), 819–828.
<https://doi.org/10.1053/j.ajkd.2011.12.023>
- Okuno, S., Ishimura, E., Kohno, K., Fujino-Katoh, Y., Maeno, Y., Yamakawa, T., Inaba, M., & Nishizawa, Y. (2009). Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, 24(2), 571–577. <https://doi.org/10.1093/ndt/gfn521>
- Palmer, S. C., Rabindranath, K. S., Craig, J. C., Roderick, P. J., Locatelli, F., & Strippoli, G. F. M. (2012). High-flux versus low-flux membranes for end-stage kidney disease. *The Cochrane Database of Systematic Reviews*, 2012(9), CD005016. <https://doi.org/10.1002/14651858.CD005016.pub2>
- Penne, E. L., Van Der Weerd, N. C., Blankestijn, P. J., Van Den Dorpel, M. A., Grooteman, M. P. C., Nubé, M. J., Ter Wee, P. M., Lévesque, R., & Bots, M. L. (2010). Role of residual kidney function and convective volume on change in β 2-microglobulin levels in hemodiafiltration patients. *Clinical Journal of the American Society of Nephrology*, 5(1), 80–86.

<https://doi.org/10.2215/CJN.03340509>

- PERNEFRI. (2019). 11th Report of Indonesian Renal Registry. *Indonesian Renal Registry (IRR)*, 11, 1–46.
- PERNEFRI. (2023). 13th Annual Report of Indonesian Renal Registry. *Indonesian Renal Registry (IRR)*, 13, 1–37.
[https://www.indonesianrenalregistry.org/data/IRR 2018.pdf](https://www.indonesianrenalregistry.org/data/IRR%2018.pdf)
- Pomarè Montin, D., Ankawi, G., Lorenzin, A., Neri, M., Caprara, C., & Ronco, C. (2018). Biocompatibility and Cytotoxic Evaluation of New Sorbent Cartridges for Blood Hemoperfusion. *Blood Purification*, 46(3), 187–195.
<https://doi.org/10.1159/000489921>
- Puspitasari, M., Afiatin, Oktaria, V., Wardhani, Y., & Wijaya, W. (2024). Five-year survival analysis and predictors of mortality of adult hemodialysis patients in Indonesia: a nationwide database analysis. *International Urology and Nephrology*, 56(11), 3657–3664. <https://doi.org/10.1007/s11255-024-04118-1>
- Ravani, P., Palmer, S. C., Oliver, M. J., Quinn, R. R., MacRae, J. M., Tai, D. J., Pannu, N. I., Thomas, C., Hemmelgarn, B. R., Craig, J. C., Manns, B., Tonelli, M., Strippoli, G. F. M., & James, M. T. (2013). Associations between hemodialysis access type and clinical outcomes: a systematic review. *Journal of the American Society of Nephrology: JASN*, 24(3), 465–473.
<https://doi.org/10.1681/ASN.2012070643>
- Ricci, Z., Romagnoli, S., Reis, T., Bellomo, R., & Ronco, C. (2022). Hemoperfusion in the intensive care unit. *Intensive Care Medicine*, 48(10), 1397–1408. <https://doi.org/10.1007/s00134-022-06810-1>
- Ronco, C., & Bellomo, R. (2022). Hemoperfusion: technical aspects and state of the art. *Critical Care*, 26(1), 1–12. <https://doi.org/10.1186/s13054-022-04009-w>
- Sam, R. (2014). Hemodialysis: Diffusion and Ultrafiltration. *Austin J Nephrol Hypertens. Austin J Nephrol Hypertens*, 1(1), 1010–1012.
- Scarpioni, R., Ricardi, M., Albertazzi, V., De Amicis, S., Rastelli, F., & Zerbini, L. (2016). Dialysis-related amyloidosis: challenges and solutions. *International Journal of Nephrology and Renovascular Disease*, 9, 319–328.
<https://doi.org/10.2147/IJNRD.S84784>
- Sedighi, O., Abediankenari, S., & Omranifar, B. (2015). Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease. *Nephro-Urology Monthly*, 7(1), e23563.
<https://doi.org/10.5812/numonthly.23563>
- Shi, F., Sun, L., & Kaptoge, S. (2021). Association of beta-2-microglobulin and cardiovascular events and mortality : A systematic review and meta-analysis. *Atherosclerosis*, 320(January), 70–78.
<https://doi.org/10.1016/j.atherosclerosis.2021.01.018>
- Smith, L. K., He, Y., Park, J.-S., Bieri, G., Snethlage, C. E., Lin, K., Gontier, G., Wabl, R., Plambeck, K. E., Udeochu, J., Wheatley, E. G., Bouchard, J., Eggel, A., Narasimha, R., Grant, J. L., Luo, J., Wyss-Coray, T., & Villeda, S. A. (2015). β 2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. *Nature Medicine*, 21(8), 932–937.
<https://doi.org/10.1038/nm.3898>
- Susantitaphong, P., Siribamrungwong, M., & Jaber, B. L. (2013). Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-

- analysis of randomized controlled trials. *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, 28(11), 2859–2874. <https://doi.org/10.1093/ndt/gft396>
- Taylor, M. J., Hanson, C. S., Casey, J. R., Craig, J. C., Harris, D., & Tong, A. (2016). “You know your own fistula, it becomes a part of you”--Patient perspectives on vascular access: A semistructured interview study. In *Hemodialysis international. International Symposium on Home Hemodialysis* (Vol. 20, Nomor 1, hal. 5–14). <https://doi.org/10.1111/hdi.12340>
- Thompson, S., James, M., Wiebe, N., Hemmelgarn, B., Manns, B., Klarenbach, S., & Tonelli, M. (2015). Cause of Death in Patients with Reduced Kidney Function. *Journal of the American Society of Nephrology: JASN*, 26(10), 2504–2511. <https://doi.org/10.1681/ASN.2014070714>
- Thurlow, J. S., Joshi, M., Yan, G., Norris, K. C., Agodoa, L. Y., Yuan, C. M., & Nee, R. (2021). Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. *American Journal of Nephrology*, 52(2), 98–107. <https://doi.org/10.1159/000514550>
- Topçiu-Shufta, V., Miftari, R., Haxhibeqiri, V., & Haxhibeqiri, S. (2016). Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients. *Medical Archives (Sarajevo, Bosnia and Herzegovina)*, 70(5), 348–350. <https://doi.org/10.5455/medarh.2016.70.348-350>
- Trowsdale, J., & Knight, J. C. (2013). Major histocompatibility complex genomics and human disease. *Annual Review of Genomics and Human Genetics*, 14, 301–323. <https://doi.org/10.1146/annurev-genom-091212-153455>
- Uji, Y., Motomiya, Y., & Ando, Y. (2009). A circulating β 2-microglobulin intermediate in hemodialysis patients. *Nephron - Clinical Practice*, 111(3), 173–182. <https://doi.org/10.1159/000199457>
- Urquhart-Secord, R., Craig, J. C., Hemmelgarn, B., Tam-Tham, H., Manns, B., Howell, M., Polkinghorne, K. R., Kerr, P. G., Harris, D. C., Thompson, S., Schick-Makaroff, K., Wheeler, D. C., van Biesen, W., Winkelmayer, W. C., Johnson, D. W., Howard, K., Evangelidis, N., & Tong, A. (2016). Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, 68(3), 444–454. <https://doi.org/10.1053/j.ajkd.2016.02.037>
- Vadakedath, S., & Kandi, V. (2017). Dialysis: A Review of the Mechanisms Underlying Complications in the Management of Chronic Renal Failure. *Cureus*, 9(8). <https://doi.org/10.7759/cureus.1603>
- Vanholder, R., Annemans, L., Brown, E., Gansevoort, R., Gout-Zwart, J. J., Lameire, N., Morton, R. L., Oberbauer, R., Postma, M. J., Tonelli, M., Biesen, W. Van, & Zoccali, C. (2017). Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. *Nature Reviews. Nephrology*, 13(7), 393–409. <https://doi.org/10.1038/nrneph.2017.63>
- Watanabe, Y., Kawanishi, H., Suzuki, K., Nakai, S., Tsuchida, K., Tabei, K., Akiba, T., Masakane, I., Takemoto, Y., Tomo, T., Itami, N., Komatsu, Y., Hattori, M., Mineshima, M., Yamashita, A., Saito, A., Naito, H., Hirakata, H., & Minakuchi, J. (2015). Japanese Society for Dialysis Therapy Clinical

- Guideline for “Maintenance Hemodialysis: Hemodialysis Prescriptions.” *Therapeutic Apheresis and Dialysis*, 19(S1), 67–92. <https://doi.org/10.1111/1744-9987.12294>
- Winchester, J. F., Salsberg, J. A., & Levin, N. W. (2003). Beta-2 Microglobulin in ESRD: An In-Depth Review. *Advances in Renal Replacement Therapy*, 10(4), 279–309. <https://doi.org/10.1053/j.arrt.2003.11.003>
- Wuerzner, G., Firsov, D., & Bonny, O. (2014). Circadian glomerular function: From physiology to molecular and therapeutical aspects. *Nephrology Dialysis Transplantation*, 29(8), 1475–1480. <https://doi.org/10.1093/ndt/gft525>
- Yeung, E., Bello, A. K., Levin, A., Lunney, M., Osman, M. A., Ye, F., Ashuntantang, G., Bellowin-Font, E., Benghanem Gharbi, M., Davison, S., Ghnaimat, M., Harden, P., Jha, V., Kalantar-Zadeh, K., Kerr, P., Klarenbach, S., Kovesdy, C., Luyckx, V., Neuen, B., ... Johnson, D. (2021). Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. *BMJ Open*, 11(7), e047245. <https://doi.org/10.1136/bmjopen-2020-047245>
- Zhang, Y., Mei, C. L., Rong, S., Liu, Y. Y., Xiao, G. Q., Shao, Y. H., & Kong, Y. Z. (2015). Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients under Maintenance Hemodialysis. *Blood Purification*, 40(2), 127–132. <https://doi.org/10.1159/000376604>
- Zhao, D., Wang, Y., Wang, Y., Jiang, A., Cao, N., He, Y., Wang, J., Guo, Z., Liu, W., Shi, W., Hao, L., Li, J., Li, W., Wang, C., Wang, J., Lin, H., Shi, W., Wang, L., Jiang, H., ... Chen, X. (2022). Randomized Control Study on Hemoperfusion Combined with Hemodialysis versus Standard Hemodialysis: Effects on Middle-Molecular-Weight Toxins and Uremic Pruritus. *Blood Purification*, 1–11. <https://doi.org/10.1159/000525225>
- Zhao, F., Wang, Z., Liu, L., & Wang, S. (2017). The influence of mortality rate from membrane flux for end-stage renal disease: A meta-analysis. *Nephrologie & Therapeutique*, 13(1), 9–13. <https://doi.org/10.1016/j.nephro.2016.07.445>
- Zhen, J., Liu, S., Kam, R. Y. L., Zhao, G., Peng, H., Liang, J., Xu, A., Li, C., Ren, L., Wu, J., & Cheung, B. M. Y. (2023). Association of beta-2-microglobulin, cystatin C and lipocalin-2 with stroke risk in the general Chinese population. *Annals of Medicine*, 55(1), 2203516. <https://doi.org/10.1080/07853890.2023.2203516>